Serotonin and hallucinogens

Neuropsychopharmacology

Volumn 21, Issue , 1999, Pages 16S-23S

  Aghajanian, G K ^a   Marek, G J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT2A receptors; Cerebral cortex; Excitatory postsynaptic potentials; Glutamatergic; Hallucinogens; Locus coeruleus; LSD; Serotonin

Indexed keywords

GLUTAMIC ACID; INDOLEAMINE; LYSERGIDE; MESCALINE; PHENETHYLAMINE DERIVATIVE; PSYCHEDELIC AGENT; SEROTONIN; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR;

BRAIN CORTEX; COGNITIVE DEFECT; DENDRITE; DRUG ANTAGONISM; EXCITATORY POSTSYNAPTIC POTENTIAL; LOCUS CERULEUS; PERCEPTION DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PYRAMIDAL NERVE CELL; REVIEW;

ANIMALS; CEREBRAL CORTEX; HALLUCINOGENS; HUMANS; PYRAMIDAL CELLS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 0032868038     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00135-3     Document Type: Article

References (49)

1. Aghajanian GK (1980): Mescaline and LSD facilitate the acti-vation of locus coeruleus neurons by peripheral Stimuli. Brain Res 186:492-498
2. Aghajanian GK (1995): Electrophysiology of serotonin recep-tor subtypes and signal transduction mechanisms. In Bloom FE, Kupfer DJ (eds), Psychopharmacology: TheFourth Generation of Progress. New York, Raven Press, pp 451-460
3. Aghajanian GK, Foote WE, Sheard MH (1968): Lysergic acid diethylamide: Sensitive neuronal units in the midbrainraphe. Science 161:706-708
4. Aghajanian GK, Foote WE, Sheard MH (1970): Action of psy-chotogenic drugs on single midbrain raphe neurons. J PharmacolExpTher 171:178-187
5. Aghajanian GK, Haigler HJ (1975): Hallucinogenic indoleamines: Preferential action upon presynaptic serotonin receptors. Psychopharmacology 1:619-629
6. Aghajanian GK, Haigler HJ, Bloom FE (1972): Lysergic acid diethylamide and serotonin: Direct actions on seroto-nin-containing neurons in rat brain. Life Sci 11:615-622
7. Aghajanian GK, Marek GJ (1997): Serotonin induces excita-tory postsynaptic potentials in apical dendrites of neo-cortical pyramidal cells. Neuropharmacology 36:589-599
8. Aghajanian GK, Marek GJ (1998): Serotonin 5-HT2Arecep-tors enhance asynchronous excitatory transmission in pyramidal cells (layer V) of prefrontal cortex. SocNeu-rosci Abs 24:1366
9. Araneda R, Andrade R (1991): 5-Hydroxytryptamine and 5-hydroxytryptamine1Areceptors mediate opposing re-sponses on membrane excitability in rat association cor-tex. Neuroscience 40:399-412
10. Aston-Jones G, Bloom FE (1981): Norepinephrine-containing locus coeruleus neurons in behaving rats exhibit pro-nounced responses to non-noxious environmental stimuli. J Neurosci 1:87-900
11. Balestrieri A, Fontanari D (1959): Acquired and crossed tol-erance to mescaline, LSD-25, and BOL-148. Arch Gen Psychiat 1:279-282
12. Bonson KR, Buckholtz JW, Murphy DL (1996): Chronic administration of serotonergic antidepressants attenu-ates the subjective effects of LSD in humans. Neuropsy-chopharmacology 14:425-436
13. Cedarbaum JM, Aghajanian GK (1978): Activation of locus coeruleus neurons by peripheral stimuli: Modulation bya collateral inhibitory mechanism. Life Sci 23:1383-1392
14. Chiang C, Aston-Jones G (1993): A 5-hydroxytryptamine agonist augments7-aminobutyric acid and excitatoryamino acid inputs to noradrenergic locus coeruleus neurons. Neuroscience 54:409-420
15. Dählstrom A, Fuxe K (1964): Evidence for the existence of monoamine containing neurons in the central nervoussystem. I. Demonstration of monoamines in the cellbodies of brain stem neurons. ActaPhysiolScand 6:1-55
16. Freedman DX (1961): Effects of LSD-25 on brain serotonin. J PharmacolExpTher 134:160-166
17. Gaddum JH, Hammeed KA (1954): Drugs that antagonize 5-hydroxytryptamine. Br J Pharmacol 9:240-248
18. Gellman RL, Aghajanian GK (1993): Pyramidal cells in piri-form cortex receive a convergence of inputs from monoamine activated GABAergic interneurons. BrainRes 600:63-73
19. Glennon RA (1990): Do classical hallucinogens act as 5-HT2 agonists or antagonists? Neuropsychopharmacology3:509-517
20. Glennon RA, Titeler M, McKenney JD (1984): Evidence for 5-HT2involvement in the mechanism of action of hallu-cinogenic agents. Life Sci 35:2502-2511
21. Goda Y, Stevens CF (1994): Two components of transmitter release at a central synapse. Pro.NatlAcadSci USA91:12942-12946
22. Haigler HJ, Aghajanian GK (1973): Mescaline and LSD: Direct and indirect effects on serotonin-containing neurons in brain. Eur J Pharmacol 21:53-60
23. Hoyer D, Clarke DE, Fozard R, Hartig PR, Martin GR, Myle-charane EJ, Saxena PR, Humphrey PPA (1994): VII. International Union of Pharmacology classification ofreceptors for 5-hydroxytryptamine (serotonin).Pharma-col Revs 46:157-203
24. Isbell H, Logan CR (1957): Studies on the diethylamide of lysergic acid (LSD-25). Arch Gen Psychiat 77:350-358
25. Jakab RL, Goldman-Rakic PS (1998): 5-Hydroxytryptamine^ serotonin receptors in the primate cerbral cortex: Possi-ble site of action of hallucinogenic and antipsychoticdrugs in pyramidal cell apical dendrites. ProcNatlAcadSci 95:735-740
26. Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, ForbesIT, Brown AM, Middlemiss DN, Blackburn TP (1997):SB 242084, a selective and brain penetrant 5-HT2Creceptor antagonist. Neuropharmacology 36:609-620
27. Li C, Bazbek CL, Davletov A, Sudhof TC (1995): Distinct Ca2+ and Sr2+ binding properties of synaptotagmins. JBiolChem 270:24898-24902
28. Lopez-Gimenez JF, Mengod G, Palacios JM, Vilaro MT (1997): Selective visualization of rat brain 5-HT2Arecep-tors by autoradiography with [3H]MDL 100, 907. Nau-nyn-Schmiedeberg's Arch Pharmacol 356:446-454
29. Marek GJ, Aghajanian GK (1996a): LSD and the phenethy-lamine hallucinogen DOI are potent partial agonists at 5-HT2Areceptors on neurons in the rat piriform cortex. JPharmacolExpTher 278:1373-1382
30. Marek GJ, Aghajanian GK (1996b): Serotonergic amplifica-tion of apically derived EPSPs in neocortical pyramidal cells. SocNeurosci Abs 22:1323
31. Marek GJ, Aghajanian GK (1998a): 5-HT-induced EPSCs in neocortical layer V pyramidal cell of prefrontal cortex:Suppression by ^ opiate receptor activation. Neuro-science 86:485-497
32. Marek GJ, Aghajanian GK (1998b): Serotonin2Areceptor-induced EPSCs in layer V pyramidal cells of prefrontal cortex: Block by group II/III metabotropic glutamateagonists. SocNeurosci Abs 24:1366
33. Mengod G, Pompeiano M, Martinez-Mir MI, Palacios JM (1990): Localization of the mRNA for the 5-HT2receptorby in situ hybridization histochemistry. Correlation withthe distribution of receptor sites. Brain Res 524:139-143
34. Pazos A, Palacios JM (1985): Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Sero-tonin-1 receptors. Brain Re. 346:205-230
35. Rapport MM, Green AA, Page IH (1948): Serum vasocon-strictor (serotonin). IV. Isolation and characterization. J BiolChem 176:1243-1251
36. Rasmussen K, Aghajanian GK (1986): Effects of hallucino-gens on spontaneous and sensory-evoked locus coer-uleus unit activity in the rat: Reversal by selective 5-HT2antagonists. Brain Res 385:95-400
37. Rasmussen K, Aghajanian GK (1988): Potency of antipsy-chotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2binding affinity. Neuropsychopharmacology 1:101-107
38. Resnick O, Krus DM, Raskin M (1964): LSD-25 action in normal subjects treated with a monoamine oxidase inhibitor. Life Sci 3:1207-1214
39. Resnick O, Krus DM, Raskin M (1965): Accentuation of the psychological effects of LSD-25 in normal subjectstreated with reserpine. Life Sci 4:1433-1437
40. Sanders-Bush E, Burris KD, Knoth K (1988): Lysergic acid diethylamide and 2, 5-dimethoxy-4-methylamphetamineare partial agonists at serotonin receptors linked tophosphoinositide hydrolysis. J PharmacolExperThera-peu 246:924-928
41. Shaw E, Woolley DW (1956): Some serotonin-like activities of lysergic acid diethylamide. Science 124:121-123
42. Sheldon PW, Aghajanian GK (1990): Serotonin (5-HT) induces IPSPs in pyramidal layer cells of rat piriformcortex: Evidence for the involvement of a 5-HT2-acti-vated interneuron. Brain Res 506:62-69
43. Tanaka E, North RA (1993): Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex. J Neurophys69:1749-1757
44. Titeler M, Lyon RA, Glennon RA (1988): Radioligand bind-ing evidence implicates the brain 5-HT2receptor as a site of action for LSD and phenylisopropylaminehallu-cinogens. Psychopharmacology 94:213-216
45. Twarog BM, Page IH (1953): Serotonin content of some mammalian tissues and urine and a method for itsdetermination. Am J Physiol 175:157-161
46. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997): Positron emission tomog-raphy and fluorodeoxyglucose studies of metabolic hyper-frontality and psychopathology in the psilocybin modelof psychosis. Neuropsychopharmacology 16:357-372
47. Willins DL, Deutch AY, Roth BL (1997): Serotonin 5-HT2Areceptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27:79-82
48. Wolbach AB, Miner EJ, Isbell H (1962): Comparison of psilo-cin with psilocybin, mescaline, and LSD-25. Psycho-pharmacologia 3:219-223
49. Woolley DW, Shaw W (1954): A biochemical and pharmaco-logical suggestion about certain mental disorders. ProcNatlAcadSci 40:228-231